ACADIA Pharmaceuticals Inc. (ACAD)

21.15
NASDAQ
Prev Close 21.20
Day Low/High 20.84 / 21.40
52 Wk Low/High 20.12 / 58.72
Exchange NASDAQ
Shares Outstanding 160.05B
Market Cap 3.39B
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Acadia Pharmaceuticals: a Tough Pill to Swallow

Acadia Pharmaceuticals: a Tough Pill to Swallow

A long repair process will be needed in the months ahead. Let's check the charts.

An All-Terrain Strategy for Portfolio Management

An All-Terrain Strategy for Portfolio Management

The market's mood seems to be changing almost daily; he's an approach for how to trade it regardless of how it's feeling on any particular day.

Bearish Bets: 2 Nasdaq Stocks You Should Consider Shorting This Week

Bearish Bets: 2 Nasdaq Stocks You Should Consider Shorting This Week

These names are displaying both technical and quantitative deterioration.

Indices Look Susceptible to a Pullback, and a Way to Play a Dinged Biopharma

Indices Look Susceptible to a Pullback, and a Way to Play a Dinged Biopharma

Various hard-charging mega-cap stocks seem overdue for a significant pause, while a drop in Acadia Pharmaceuticals sets up an options play.

3 Promising Biotech Stocks to Buy on a Market Pullback

3 Promising Biotech Stocks to Buy on a Market Pullback

Eagle Pharmaceuticals, Biohaven Pharmaceuticals and Acadia Pharmaceuticals are names to consider on a 10% move down in equities.

Acadia Pharma Rated New Buy at Jefferies

Fishing in 2 More Ponds Where Insiders Are Buying

Fishing in 2 More Ponds Where Insiders Are Buying

Acadia Pharmaceuticals and HD Supply each have seen significant insider purchases of late.

The Wisdom of Taking Profits in Small Biotech Stocks Upon FDA Drug Approval

The Wisdom of Taking Profits in Small Biotech Stocks Upon FDA Drug Approval

There are multiple reasons why these stocks often decline after their drugs receive the blessing of regulators.

The Big Challenge: Putting Idle Capital to Work Without Chasing Too Much

The Big Challenge: Putting Idle Capital to Work Without Chasing Too Much

There isn't much choice but to buy strength.

6 Top Biopharmaceutical Stock Picks You Should Know About

6 Top Biopharmaceutical Stock Picks You Should Know About

The aging population is creating a massive tailwind for companies that provide cutting-edge health care.

Positive Developments for These 3 Biotech Stocks

Positive Developments for These 3 Biotech Stocks

We review Acadia Pharmaceuticals, The Medicines Company, and Flexion Therapeutics.

2 Attractive Biotechs With Key Study Outcomes on the Horizon

2 Attractive Biotechs With Key Study Outcomes on the Horizon

Intra-Cellular Therapies and Acadia Pharmaceuticals are worth investors' attention.

3 Biotech Stocks Boasting Earnings Beats - and Healthy Outlooks

3 Biotech Stocks Boasting Earnings Beats - and Healthy Outlooks

Quick takes on fourth-quarter results from these 3 biotech names.

8 Stocks Poised to Change Direction

8 Stocks Poised to Change Direction

These names are showing technical characteristics of either bullish or bearish reversal patterns.

3 Biotech Best Bets From the 'Stock Picker of the Year'

3 Biotech Best Bets From the 'Stock Picker of the Year'

In 2017, McCamant's model portfolio rose 65%, while his trader's portfolio rose 98%.

Time to Marinate the Ice Cubes

Great being here on Daily Diary today. Nice to see a huge rally for once standing in for Dougie as well. Lots of good conversation as the markets close near their highs for the day. Some big moves in the small biotech names that are near and dear to...

A Rash of Biotech News

The April Jobs report showed that 164,000 jobs were created last month. This is nearly 30,000 jobs less than the consensus. Unemployment rates tumbles to 3.9%, the first time under the 4% level in almost two decades. A rash of biotech news hitting t...

3 Good Bargain Stocks With Insider Buying

3 Good Bargain Stocks With Insider Buying

I continue to keep a 'shopping list' at the ready for the next dip in the market.

Multiple Creep... and More

Recently I have noticed some of Wall Street's younger analysts engaging in "multiple creep." They seem to be treating a 12 EBITD (cash flow) multiple like a 12 PE (price to earnings) ratio. Whoops! No problem, for example, paying 25x EPS for ....Unt...

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

The biotech sector has seen a big rally, but there are still opportunities.

Acadia, Dynavax Make the Biotech Mailbag

Acadia, Dynavax Make the Biotech Mailbag

Readers have asked about Acadia Pharmaceuticals and Dynavax Technologies, so we answer.

The Good, the Bad and the Ugly (Monday Edition)

"If you work for a living, why do you kill yourself working?" -- Tuco, The Ugly: "The Good, the Bad and the Ugly" There was plenty of sector rotation today (but little overall movement), so let's move to the abbreviated Monarch Notes form of "Takeaw...

Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers

Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers

The Plymouth Meeting, Pa.-based firm said a Phase 1 study of Zika vaccine GLS-5700 'induced high levels of binding antibodies in 100% of participants.'

Biotech M&A: Who's Next After Gilead-Kite?

Biotech M&A: Who's Next After Gilead-Kite?

Prospects for acquisition activity in the sector are improving.

'Longing' for Acadia Pharmaceuticals? Here's How to Play It

'Longing' for Acadia Pharmaceuticals? Here's How to Play It

ACAD looks strong enough for a rally at least to the upper $30s.